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Introduction: Natural surfactants have been shown to be superior to synthetic
surfactants in the treatment of neonatal respiratory distress syndrome (RDS). In
Germany, Alveofacts (A) and Curosurfs (C) are the most frequently used natural
surfactant preparations. The aim of this retrospective, observational study was to
compare the effects of A and C on gas exchange and outcome in premature infants.
Methods: During a 5-year period in our neonatal intensive care unit (NICU), 187
premature infants were treated with surfactant, with 82 receiving A and 105
receiving C. We recorded FIO2 and gas exchange (PaO2/FIO2 ratio, PaCO2, SaO2)
during the first 72 h after surfactant application and the incidence of outcome
parameters at day 28 (bronchopulmonary dysplasia (BPD), intraventricular hemor-
rhage (IVH grade III or IV), patent ductus arteriosus (PDA), pneumothorax,
necrotizing enterocolites (NEC) and death). The differences between the patient
groups were assessed by ANOVA or the calculation of relative risks. Bonferroni
correction was used for multiple comparisons.
Results: There were no statistically significant differences between infants treated
with A and C in mean gestational age (28.4 vs. 28.4 weeks), birth weight (1210
vs.1258 g) and time of first surfactant application (60 vs. 90min postnatal).Elsevier Ltd. All rights reserved.
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H. Proquitte´ et al.170We observed no significant between group differences in course of FIO2 and blood
gases, or in incidence at day 28 of BPD (41.7% vs. 42.8%), IVH III/IV (18.3% vs. 14.3%),
pneumothorax (9.8% vs. 4.8%), PDA (23.2% vs. 21.9%), PVL (7.3% vs. 9.5%) and death
(17% vs. 17.1%). There were also no statistically significant differences in the
subgroup of infants o28 weeks. The lower incidence of NEC in A compared with C
(1.2% vs. 10.5%, P ¼ 0:01) was not statistically significant after Bonferroni
correction.
Conclusion: Independent of gestational age no significant difference in the clinical
efficacy of A and C was observed.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Surfactant therapy reduces mortality1,2 and mor-
bidity3 of preterm infants with respiratory distress
syndrome (RDS). Various surfactant preparations
are commercially available. Since large clinical
trials showed that naturally derived surfactants had
superior efficacy when compared with synthetic
surfactant preparations,1 natural preparations are
now used almost exclusively.
Various natural surfactants, derived from different
animals, have been developed and tested.1,3–6 These
commercially available preparations differ in their
contents and composition, as well as in their in
vitro7–9 and in vivo5,6,10,11 activity. A recent retro-
spective analysis by Clark et al.2 comparing the
natural surfactants Infasurfs and Survantas in a
large series of neonates found no significant differ-
ences in mortality. In a prospective comparison by
Baroutis et al.3 of three natural surfactants (Alveo-
facts (A), Curosurfs (C) and Survantas (S)) in infants
with RDS, significant differences in clinical outcome
with regard to C and S were observed. C was superior
with regard to fewer days on mechanical ventilation
(Po0:043) and fewer days on supplemental oxygen
(Po0:04). Beyond that a reduced length of stay in
hospital (LOS) of C compared to S (Po0:027) and A
(Po0:04) was observed. Additionally, in another
prospective comparison of C and S by Ramanathan
et al.,12 a significantly reduced FIO2 requirement was
observed in C and a higher initial dose of C (200mg)
was associated with significantly reduced mortality
(Po0:05).
In Germany, bovine-derived Alveofacts (A; Boeh-
ringer Ingelheim Pharma, Ingelheim, Germany) and
porcine-derived Curosurfs (C; Nycomed Pharma,
Ismaning, Germany) are the most frequently used
natural surfactant preparations, each of which has
been independently tested in large clinical
trials.13–16 Although these surfactant preparations
contain surfactant-associated proteins B and C,
their lipid compositions differ significantly. Further-
more, the total volume (in mL) to be applied on thebasis of a comparable surfactant quantity (in mg) is
significantly higher for C than for A. Plasmalogens
and polyunsaturated fatty acid containing phos-
pholipids (PUFA-PL), which improve the surface
properties of lipid mixtures, are significantly higher
in C than in A.17 A higher concentration of PUFA-PL
and plasmalogen in tracheal aspirates of preterm
infants immediately after birth has been associated
with a lower incidence of bronchopulmonary
dysplasia (BPD).18
The differences between A and C in composition,
dosage and viscosity are evident. We speculated
that these differences may affect the clinical
efficiency. Therefore, the aim of this study was to
compare the immediate response to surfactant
administration and long-term outcome parameters
in infants treated with A and C.Patients and methods
A prospective schedule for administration of exo-
genous surfactant was introduced into our neonatal
intensive care unit (NICU) in 1995. Every infant
requiring surfactant therapy, as judged by the
attending neonatologist, received 100mg/kg of A
or C, with the surfactant changed quarterly.
Surfactant was not blinded and administered by a
rapid bolus injection into the distal endotracheal
tube, while disconnected from conventional me-
chanical ventilation. After surfactant administra-
tion, no manual bagging was applied. Conventional
ventilation was continued using the same adjust-
ments of the ventilator as before surfactant
administration.19
We performed a retrospective analysis of data
from all premature infants (gestational age o32
weeks) that received surfactant between 1996 and
2000. Infants included were those who showed signs
of RDS20 and required mechanical ventilation with a
FIO2 higher than 0.3. Thirty-six infants with meco-
nium aspiration syndrome or severe congenital
anomalies, or those who received their first dose
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excluded from analysis. To assess the effect of
gestational age on clinical efficiency a subgroup
analysis of infants o28 weeks was performed.
Data obtained from patient charts included
gestational age, birth weight, sex and multiple
births, prenatal administration of steroids, mode of
delivery, and APGAR scores at 1 and 5min. To
estimate the initial effect of surfactant therapy, we
recorded FIO2, PaO2/FIO2, PaCO2 and SaO2 before
and 1, 2, 6, 12, 24, 48 and 72 h after surfactant
application. To determine clinical outcome, we
obtained data from patient charts regarding the
presence of BPD, defined as oxygen dependency at
day 2821; necrotizing enterocolites (NEC)22; hemo-
dynamically significant patent ductus arteriosus
(PDA)23; intraventricular hemorrhage (IVH) of grade
III and higher24; periventricular leucomalacia
(PVL)25; pulmonary bleeding; and air leaks or
pulmonary intestinal emphysema.26
The statistical significance of differences be-
tween A- and C-treated infants was tested by the
w2-test or the Fisher’s Exact test for qualitative
data and by ANOVA or Kruskal–Wallis test for
quantitative variables as appropriated. The treat-
ment effect on outcome parameters was assessed
by the calculation of relative risks. Time-based
analyses of days on ventilator and LOS, as well as
age at the time the infant was weaned to room air
were presented as Kaplan–Meier curves. Statistical
analysis was performed using the software STAT-
GRAPHICS Plus (Version 5, Manugistics Inc., Rock-
ville, MD, USA). Statistical significance was defined
as a P-valueo0.05. Bonferroni correction was used
for multiple comparisons.Results
Of 223 infants receiving surfactant during the study
period in our NICU, 36 had to be excluded fromTable 1 Comparison of patient characteristics of th
percentages in brackets or mean7SD).
Alveofacts (N ¼ 8
GA (SSW) 28.472.9
Birth weight (g) 12107521
Male gender, N (%) 50 (60.9)
Twins or more, N (%) 19 (23.2)
No maternal steroids, N (%) 36 (43.9)
Caesarean section, N (%) 59 (71.9)
APGAR 1min p5, N (%) 55 (67.9)
APGAR 5min p5, N (%) 13 (16)
Significance level after Bonferroni correction was Po0:006. No st
groups (A and C) were observed.subsequent analysis because they fulfilled the
exclusion criteria. Of the 187 infants whose charts
were analyzed, 82 received A and 105 received C.
Perinatal data of both treatment groups are
shown in Table 1. After Bonferroni correction, there
was no statistically significant difference in all data
between the A- and C-treated infants.Immediate surfactant response
When we analyzed data on surfactant administra-
tion, we observed no significant differences be-
tween the two groups of infants (Table 2). Neither
application time nor the number of repeat admin-
istrations of surfactant differed significantly. The
cumulative surfactant dosage was 2087141mg/kg
in infants administered A and 183795mg/kg in
infants administered C (P40:05).
Changes in FIO2 and blood gases after surfactant
instillation are shown in Fig. 1(a–d). In both groups,
the PaO2/FIO2 ratio and SaO2 significantly increased
after surfactant administration (Po0:001) and
remained higher during the subsequent 72 h. The
PaCO2 significantly decreased after surfactant
administration (Po0:05). When we compared the
two groups, however, we observed no significant
differences in any of the parameters shown (Fig. 1).Long term outcome parameters
The outcome parameters are summarized in Fig. 2.
Again, we did not detect any statistically significant
differences between infants administered A and
those administered C. The incidence of BPD was
nearly identical in the two groups (41.5% for A and
42.8% for C). The only difference between the two
treatment groups was the incidence of NEC (1.2%
for A vs. 10.5% for C, P ¼ 0:01). After Bonferroni
correction, however, this difference was not
statistically significant.e two treatment groups (shown are numbers with
2) Curosurfs (N ¼ 105) P-value
28.473.0 0.9
12587681 0.59
62 (59) 0.78
24 (22.8) 0.22
48 (45.7) 0.89
91 (86.7) 0.02
73 (70.2) 0.79
19 (18.3) 0.96
atistically significant differences between the two treatment
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Table 2 Time of first surfactant administration (median and range) and number of infants requiring more than
one administration (number with percentages in brackets).
Alveofacts Curosurfs P-value
1st application, min (range) 60 (20–150) 90 (30–180) 0.34
2 applications, N (%) 18 (21.9) 27 (25.7) 0.41
3 applications, N (%) 21 (25.6) 21 (20) 0.57
4 applications, N (%) 7 (8.5) 4 (3.8) 0.46
5 applications, N (%) 2 (2.4) 1 (0.9) 0.53
Significance level after Bonferroni correction was Po0:01. No statistically significant differences between the two treatment
groups (A and C) were observed.
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Figure 1 Values of FIO2, PaO2/FIO2, PaCO2 and SaO2 (mean7SD) within the first 72 h after application of surfactant.
Dotted line: C group; solid line, A group. No statistically significant differences in any of these parameters were
observed.
H. Proquitte´ et al.172We also observed no statistically significant
differences between A and C in the median
duration of artificial ventilation (6.5 d (range,
2–24 d) vs. 6.0 d (range, 2–16 d)), duration of O2
supplementation (20 d (range, 6–43 d) vs. 18 d
(range, 5–44 d)) and the LOS (60 d (range,
26–89 d) vs. 59 d (range, 29–83 d)). Mortality was
almost identical in the two groups (17.0% for A vs.
17.1% for C). To further demonstrate the effects of
A and C on outcome Kaplan–Meier curves (Fig.
3a–c) were used showing the days on ventilatorysupport including CPAP (Fig. 3a), the days on
supplemental oxygen (Fig. 3b) and the LOS in
hospital (Fig. 3c). In neither of these curves
a significant difference between A and C was
detected.
A subgroup analysis in infants o28 and X28
weeks did not show statistically significant
differences in all investigated parameters bet-
ween A and C. To exemplify this result typical
long-term outcome parameters are shown in
Table 3.
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0.01 0.1 1 10
Favours Alveofact® Favours Curosurf ®
Emphysema
Pneumothorax
Pulmon. Hemorrhage
PVL
IVH Grade 3/4
PDA
NEC
BPD
Relative Risk 
(95% CI)
Relative Risk 
(95% CI)
2 (2.4)
8 (9.7)
4 (4.8)
6 (7.3)
15 (18.3)
19 (23.2)
1 (1.2)
34 (41.5)
3 (2.8)
5 (4.8)
7 (6.7)
10 (9.5)
15 (14.3)
23 (21.9)
11 (10.5)
45 (42.8)
0.85 (0.15 - 5.0)
2.05 (0.7 - 6.03)
0.73 (0.22 - 2.41)
0.77 (0.2 - 2.03)
1.28 (0.67 - 2.46)
1.06 (0.62 - 1.81)
0.12 (0.02 - 0.88)
0.97 (0.69 - 1.36)
Curosurf®
(N=105), n (%)
Alveofact®
(N=82), n (%)
Figure 2 Incidence of long-term outcome parameters (number and percentage in brackets) and relative risk with 95%
CI. Significance level after Bonferroni correction was Po0:006. There were no statistically significant between group
differences in any of the outcome parameters. Abbreviations: PVL, periventricular leucomalacia; IVH, intraventricular
hemorrhage; PDA, patent ductus arteriosus; NEC, necrotizing enterocolitis; BPD, bronchopulmonary dysplasia.
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Figure 3 (a–c) Kaplan–Meier curves showing the days on ventilatory support including CPAP (a), the days on
supplemental oxygen (b) and the length of stay in hospital (c). Between Alveofact (black line) and Curosurf (gray line)
there were no statistically significant between group differences in any of the outcome parameters.
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Table 3 Comparison of outcome parameters of both treatment groups (A and C) in infantso28 andX28 weeks
of gestation.
Alveofacts Curosurfs P-value
Gestational age o28 weeks
N 42 48
More than 1 surf. application (N) 27 28 0.72
BPD (N) 25 32 0.63
IVH (N) 12 11 0.71
Ventilator days, median (range) 12 (1–148) 17 (1–58) 0.61
Length of stay, median (range) 80 (1–258) 78 (1–136) 0.74
Gestational age X28 weeks
N 40 57
More than 1 surf. application (N) 12 20 0.77
BPD (N) 9 13 0.46
IVH (N) 3 4 0.76
Ventilator days, median (range) 3 (1–44) 3 (1–175) 0.71
Length of stay, median (range) 47 (1–332) 56 (1–175) 0.22
In both subgroups no statistically significant differences between A and C were found.
H. Proquitte´ et al.174Discussion
When we compared clinical data of preterm infants
treated with either Alveofacts or Curosurfs, we
found that these two surfactants did not differ with
regard to the immediate response to surfactant
administration (as determined by FIO2 and blood
gases), the required dosage of surfactant, or the
long-term outcome parameters. Thus, neither of
these surfactant preparations seemed to be super-
ior to the other. This, moreover, is clearly depicted
in the Kaplan–Meier curves (Fig. 3a–c). Neither in
days on ventilatory support and days and oxygen
dependency nor the LOS any significant difference
between A and C was found.
In this study we investigated infants o32 weeks
of gestation with mean body weight of about
1200 g, which may include mild RDS patients
with higher gestational age. Their inclusion could
mask the difference between both surfactants A
and C. However, a subgroup analysis in infantso28
and X28 weeks of gestation did not show any
statistically significant differences in the short- and
long-term parameters. Thirty-six infants of the
enrolled patients fulfilled the exclusion criteria.
An intention to treat analysis showed that the
excluded patients did not affect the results of the
study.
Although the incidence of NEC in infants treated
with C was higher than in infants treated with A,
the clinical importance of this difference is not
clear, due to the small number of infants with NEC.
Moreover, it was not statistically significant after
Bonferroni correction. This difference may have
been due to random causes, because clinicalstudies of Curosurfs12,16,27 have reported no
increased risk for NEC.
Except for one study by Baroutis et al.,3 there
have been no direct comparisons of A and C, the
two most frequently used surfactant preparations
in Germany. The characteristics of our study cohort
were similar to those observed in other studies of
surfactants,3,28 and these characteristics did not
differ between the groups of patients treated with
A and C. The indication for surfactant application
was identical for both treatment groups and was in
agreement with previous studies and the recom-
mendations of a German workshop.29 Premature
infants (o32 weeks of gestation) with RDS,20 as
judged by the attending neonatologist, received
100mg/kg of either A or C if the FIO2 was higher
than 0.3 to achieve SaO2 488%. We used the same
threshold of FIO2 as in other clinical studies of
surfactant therapy,3,12 in that we excluded infants
with meconium aspiration syndrome and severe
congenital anomalies.
The present study included only those infants
who received their first surfactant administration
within 3 h of birth. Early administration is recom-
mended30 and previous studies have performed it
within 43 or 6 h12 of birth. Our median time of
surfactant administration was distinctly shorter for
both A (60min; range, 20–150min) and C (90min;
range, 30–180min). The first surfactant adminis-
tration in our study was comparable with those of
previous studies at this time.14,15 These findings do
not exclude that a clinically relevant difference
may have existed. As recently shown12 30min
difference may be clinically and physiologically
important, enhancing for example the response to
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surfactant application was not widely accepted
practice at the time when the study was per-
formed. Meanwhile clinical practice is evolving
such that surfactant is being used when indicated
within 30min of age in preterm infants intubated
for respiratory distress.
In accordance with standard practice in Ger-
many,29 surfactant was injected into the distal
endotracheal tube by a rapid bolus, while the
patient was disconnected from conventional me-
chanical ventilation, and manual bagging was not
applied thereafter. The negative effect of bagging
on surfactant efficacy meanwhile provides support
for this procedure.31–33 After surfactant adminis-
tration, conventional ventilation was continued
using the same ventilator settings as before to
rapidly establish normal lung volume without
vigorous ventilation.
We observed no statistically significant differ-
ences in cumulative dosage of A and C or in the
number of repeat surfactant applications (Table 2).
Interestingly, the recommended dosages for A,
50–100mg/kg3,28 differ from those for C,
100–200mg/kg.3,12 In our study, the initial dosage
ought to be 100mg/kg irrespective of the surfac-
tant used. This has been the clinical practice in our
unit during the study period. We, however,
acknowledge that recent studies12,34 have consis-
tently shown that using 200mg/kg initial dose of C
resulted in faster weaning of FIO2 compared to
Survanta and was even associated with decreased
mortality. The total dosage of A, however, was
208mg/kg, which is higher than the recommenda-
tions and actually related to the repetitive applica-
tion. By contrast, the total dosage of C was 183mg/
kg, which is in the recommended range. Although
not statistically significantly different between A
and C it is not known, however, if a higher dosage of
C would have affected the outcome of our study.
Unlike the dosage, the instilled volume of both
surfactants differed significantly (4.973.4mL in A
vs. 2.771.4mL in C, Po0:05) due to the differ-
ences in the dilution (A: 120mg in 2.4mL, C:
120mg in 1.5mL) supporting that type of surfactant
used did not have any influence on clinical
outcome.
We recently showed that C has higher concentra-
tions of plasmalogens and PUFA-PL when compared
with A.17 Plasmalogens and PUFA-PL improve the
surface properties of lipid mixtures. Furthermore,
high concentrations PUFA-PL and plasmalogen in
the tracheal aspirates of preterm infants were
associated with a lower incidence of BPD.18 Thus,
we expected that C would have greater clinical
benefit than A, due to the higher plasmalogen andPUFA-PL concentrations in the former. We found,
however, that these two preparations had similar
clinical benefits. There may be several reasons for
this.
First, our study had some methodological limita-
tions. Although the allocation to each group was
prospectively randomized by quarterly changes in
the use of these surfactant preparations, the
intervention was not blinded. However, since a
large number of patients were treated, there is less
likelihood for bias in the analyzed parameters.
Second, the impact of the exogenous surfactant
on the overall lipid composition of endogenous
surfactant may be too small or too short lived to
exhibit any clinical effects. We did not analyze lipid
composition after surfactant administration; there-
fore, we do not know whether surfactant adminis-
tration altered overall lipid composition.
Third, the lower viscosity of Curosurf should lead
to better distribution of surfactant. However, we
did not observe any differences in oxygenation
following surfactant administration. Thus, the
clinical relevance of low viscosity remains unclear.
In summary, despite the differences in composi-
tion and biophysical properties of the two surfac-
tant preparations, A and C, we observed no
statistically significant differences in gas exchange
and outcome parameters in preterm infants treated
with these two preparations. Thus, large clinical
studies are further necessary to assess the clinical
efficiency of new surfactants, in particular for the
newer peptide containing synthetic surfactants.35Acknowledgments
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